Recent News

• 08.04.2026 - ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
• 07.29.2026 - ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
• 06.01.2026 - ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
• 05.22.2026 - ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
• 05.22.2026 - ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
• 05.20.2026 - ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
• 05.19.2026 - ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
• 05.18.2026 - ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
• 05.16.2026 - ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
• 05.07.2026 - ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

Recent Filings

• 07.30.2026 - 8-K Current report
• 07.30.2026 - EX-99.1 EX-99.1
• 07.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.02.2026 - 144 Report of proposed sale of securities
• 07.01.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.01.2026 - 144 Report of proposed sale of securities
• 06.30.2026 - 144 Report of proposed sale of securities
• 06.29.2026 - 144 Report of proposed sale of securities
• 06.26.2026 - 4 Statement of changes in beneficial ownership of securities